Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BIO, PhRMA Medicare Payment Rule Comments Seek “Interim” Increase

Executive Summary

Industry trade associations are proposing that Medicare reimburse non-pass-through drugs at no less than 88% of AWP in 2004 while CMS reworks its payment setting methodology

You may also be interested in...



Medicare Implements AWP-5% Payment Rate For “Uncoded” Drugs

The Centers for Medicare & Medicaid Services is implementing a provision of the 2003 Medicare law that establishes an AWP-5% payment rate for drugs covered by the Outpatient Prospective Payment System that have not yet received a reimbursement code

Medicare Implements AWP-5% Payment Rate For “Uncoded” Drugs

The Centers for Medicare & Medicaid Services is implementing a provision of the 2003 Medicare law that establishes an AWP-5% payment rate for drugs covered by the Outpatient Prospective Payment System that have not yet received a reimbursement code

Genzyme Cerezyme Medicare Outpatient Payment Set At 94% Of AWP

Genzyme's Cerezyme and Ceredase will be reimbursed at 94% of average wholesale price under the final rule for 2004 reimbursement within the Medicare Hospital Outpatient Prospective Payment System

Related Content

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel